Venous thromboembolism (VTE) refers to a hypercoa gulable state that remains an important and preven table factor in the surgical treatment of malignancies. VTE includes two identical entities with regards to deep vein thrombosis and pulmonary embolism. The incidence of VTE after major abdominal interventions for gastro intestinal, hepatobiliary and pancreatic neoplastic disor ders is as high as 25% without prophylaxis. Prophylactic use of classic or lowmolecularweight heparin, antiXa factors, antithrombotic stocking, intermittent pneumatic compression devices and early mobilization have been described. Nevertheless, thromboprophylaxis is often dis continued after discharge, although a serious risk may persist long after the initial triggering event, as the coagu lation system remains active for at least 14 d postopera tively. The aim of this review is to evaluate the results of the current practice of VTE prevention in cancer patients undergoing major abdominal surgical operations, with special attention to adequately elucidated guidelines Core tip: Venous thromboembolism (VTE) refers to a hypercoagulable state that remains an important and preventable factor in the surgical treatment of mali gnancies. The incidence of VTE after major interventions for gastrointestinal, hepatobiliary and pancreatic neo plastic disorders is as high as 25% without prophylaxis. Prophylactic use of classic or lowmolecularweight hepa rin, antiXa factors, antithrombotic stocking, intermittent pneumatic compression devices and early mobilization have been described. The aim of this review is to evaluate the results of the current practice of VTE prevention in cancer patients undergoing major abdominal surgical op erations, with attention to adequately elucidated guide lines and widely accepted protocols. 
INTRODUCTION
Venous thromboembolism (VTE) refers to a hyperco agulable state that remains an important and preventa ble factor in the surgical treatment of malignancies. VTE includes two identical entities with regards to deep vein thrombosis (DVT) and pulmonary embolism (PE) [1] . The incidence of VTE after major abdominal intervention for gastrointestinal (GI), hepatobiliary and pancreatic (HPB) neoplastic disorders is as high as 25% without prophylaxis [2] . Associated immobility, the Trendelenburg position, abdominal surgical procedure, potential com pression of the vena cava, placement of intravenous catheters and chemotherapy have been proposed as major determinants of hypercoagulation and VTE pre valence. Neoadjuvant chemoradiotherapy followed by surgical resection as well as laparoscopic techniques have also been implicated. Recent surveys suggest that mechanical and pharmacological prophylaxis is effe ctive in preventing postoperative VTE [3] . Prophylactic use of classic or lowmolecularweight heparin (LMWH), antiXa factors, antithrombotic stocking, intermittent pn eumatic compression devices and early mobilization have been alternatively described [4] . Nevertheless, th romboprophylaxis is interrupted early in many cases, while relevant risk may exist long after discharge, as the activation of the coagulation system persists for at least 2 wk postoperatively. In 2007, the American Society of Clinical Oncology (ASCO) suggested an evi dencebased clinical practice for the prophylactic and therapeutic approach to VTE. A subsequent update has recently been reported. However, there is still debate about the choice and duration of the appropriate anti coagulation therapeutic approach. Both guidelines reco mmend consideration of extended prophylaxis in high risk patients, despite the lack of a relevant, specific definition [5] . The aim of this study was to elucidate the results of the current practice of VTE prevention in cancer patients undergoing major abdominal surgical opera tions, with special attention to adequately evaluated gui delines and widely accepted protocols. In addition, recent literature is presented to provide an update on current concepts in surgical management of the disease.
HISTOLOGY AND PATHOGENESIS
Although several predisposing factors in DVT have be en meticulously investigated, mechanisms of thrombus development remain unclear. The classic Virchow triad refers to the combination of blood flow restriction, a hypercoagulable state and prothrombotic alterations in the vessel wall, and plays a pivotal role in thrombosis ini tiation [6] . Traditionally, a blood clot contains a mishmash of platelets, red blood cells and fibrin. Arterial clots are usually created under high shear stress after rupture of an atherosclerotic plaque or other vascular destruction. As they are plateletrich, administration of antiplatelet drugs is often implemented. In contrast, venous clots are fibrinrich and develop under lower shear stress on the surface of a macroscopically intact endothelium. The therapeutic approach always involves anticoagula nt drug administration [7] . Disturbed blood flow remains a significant risk parameter, as it can provoke DVT due to longterm immobilization [8] . Hypoxia activates the endo thelium, promotes the release of WeibelPalade bodies (storage granules in endothelial cells), and facilitates blo od coagulation. WeibelPalade bodies are also responsible for the production of the von Willebrand factor, which has an important pathogenetic role in platelet recruitment.
The blood coagulation cascade is welldefined and divided into the extrinsic and intrinsic pathways. Defi ciencies in the anticoagulants antithrombin and prote ins C and S constitute significant genetic risk factors that contribute to the development of a hypercoagu lable condition. Mild genetic alterations in von Leiden factor, prothrombin G20210A and fibrinogen C10034T predispose patients to decreased fibrinolysis [9] . It is co mmon knowledge that the most frequent site of throm bus formation is the valve pocket sinus due to its vertical blood flow and inadequate oxygen tension. Therefore, small thrombi initiated within the valve pocket develop slowly and extend along the inside of the vein wall, resu lting in vascular occlusion. It has been proposed that, under abnormal conditions, tissue factor (TF) is expressed on both circulating leukocytes and activated endothelial cells together with the platelet inhibitors nitric oxide and prostacyclin [10] . In addition, recent surveys demonstr ate that neutrophils accelerate thrombosis by releasing serine proteases that inactivate the anticoagulant TF pathway inhibitor, suggesting that interfering with the binding of leukocytes to the activated endothelium may represent a promising therapeutic strategy against DVT. Finally, postthrombotic syndrome describes chronic ve nous insufficiency following DVT and is attributed to ve nous hypertension, which may result from persistent thrombotic occlusion or venous valvular reflux due to a previous thrombotic condition [11] . Additionally, inflam mation may contribute to successive venous valvular damage.
CLINICAL PRESENTATION
Considering that VTE encompasses two clinical co nditions, including DVT and PE, clinical findings refer to both nosologic entities. DVT typically presents with pain and lower limb oedema, the latter being the most specific symptom. If the thrombus is located in the il eac bifurcation, pelvic veins or the inferior vena cava, bilateral rather than unilateral oedema is usually appa rent. Moreover, high partial obstruction often causes moderate oedema imitating that of heart, liver or renal insufficiency [12] . Pain with tenderness occurs in the ma jority of affected patients. Relevant clinical signs are considered nonspecific and remain independent of the size, location and extent of the thrombus. Warmth of the related limb, locoregional erythema, or discoloration and dilation of superficial veins may also be apparent. Homan's sign (calf pain on dorsiflexion of the foot) also presents in 50% of patients with DVT [13] . Furthermore, DVT should be differentially diagnosed from various other diseases including cellulitis, Baker's cyst, musculoskele tal injury, neoplasm, lymphedema, hematoma, sarco ma, venous or arterial aneurysms, and connective tissue disorders [14] . Finally, a very uncommon but hazardous form of DVT is Phlegmasia Cerulea Dolens, which is the consequence of extensive thrombotic occlusion of the major and collateral veins of a lower extremity, including the ileac and femoral veins. It is characterized by acute onset of pain, oedema, blue discoloration and swelling of the affected limb, which, if left untreated, will result in foot gangrene [15] . As far as PE is concerned, aetiology refers to air, septic and amniotic fluid emboli. Relevant clinical fin dings may vary from deadly hemodynamic collapse to progressive dyspnoea, and most patients with PE pres ent with obscure symptoms. Taking into consideration the aforementioned clinical evidence, common signs of PE include sudden dyspnoea (73%) that worsens with exertion, pleuritic chest pain (66%) deteriorating with inhalation, or exertion and a productive cough (37%) that may lead to haemoptysis (13%) [16] . Similar findings upon physical examination include tachypnoea, rales, tachycardia, fever, cardiac galloping, lower limb oedema and cyanosis.
DIAGNOSTIC MODALITIES
Several imaging studies have been proposed for DVT diagnosis. Duplex Ultrasonography (Bmode and Dopp ler) remains the current first line examination perform ed, due to noninvasiveness and absence of irradiation or contrast material [17] . Bmode is based on the principle that normal venous structures easily collapse with the pressure applied by the transducer, while veins harboring thrombi will not compress and will therefore be visible.
The Doppler colorflow imaging technique can reveal the potential adequacy of blood flow in an area where an isoechoic clot might not be depicted. Sensitivity and specificity are as high as 95% in symptomatic patients, but diminish with obesity, small and peripheral thrombi, as well as asymptomatic disease [18] . Venography with pedal vein cannulation, injection of contrast material, and serial limb radiographs remains the diagnostic modality of choice for DVT verification, with sensitivity and specificity reaching 100%. Howe ver, this technique is invasive and may induce serious consequences, such as hypersensitivity reactions, sup erficial phlebitis and renal toxicity. Another modality app lied is Impedance Plethysmography, which is sensitive and specific in proximal vein thrombosis. It measures the electrical resistance of the calf, which reflects changes in blood volume [19] . Spiral multidetectorrow CT venography from the popliteal fossa provides adequate diagnostic accuracy in association with sonographic assessment. Finally, magnetic resonance imaging remains the mo dality of choice for suspected ileac vein or inferior vena cava thrombosis, especially when CT venography is contraindicated or technically difficult [20] . Radiolabell ed peptides that tend to connect to various thrombus components have also been studied. Apcitide, a tech netiumlabelled platelet glycoprotein IIb/IIIa receptor antagonist, is proposed for diagnostic investigations of DVT. Diagnostic modalities related to DVT detection are summarized in Table 1 .
With regard to PE, common electrocardiographic abnormalities, including tachycardia, nonspecific STT disorders, right heart strain, atrial fibrillation and S1 Q3 T3 pattern, are encountered in the minority of affec ted patients [21] . CT pulmonary angiography (CTPA) is considered as the initial imaging modality of choice for stable patients [22] . CTPA reveals emboli as an intralumi nal filling defect after injection of contrast material, is noninvasive and widely available, and provides invalu able information for differential diagnosis [23] . Sensitivity and specificity are disproportionate to the size of the affected pulmonary artery. Nevertheless, PA is the cri terion standard for diagnosing PE. With the use of con trast material, a filling defect or a sharp cutoff of the problematic artery is detected in anterior, posterior and lateral studies [24] . Essential to verifying PE, Ventilation/ creased longterm risk for VTE [29] . Major abdominal cancer surgery is also a risk factor for VTE, even after hospital discharge and discontinuation of the usual perioperative prophylaxis [30] . As for laparoscopic surgery, there is still no consensus as to whether the laparoscopic or open techniques abate morbidity related to VTE. Some inve stigators state that the risk is lessened due to overall reduction in postoperative morbidity, while others claim that the impact of pneumoperitoneum increases the risk, due to compression of the inferior vena cava and iliac veins. However, existing trials are not adequate to reliably evaluate these findings [31] . Pharmacologic thromboprophylaxis is strongly reco mmended in patients with GI cancer undergoing major surgery, as risk reduction up to 80% has been proven for VTE. Current guidelines suggest LMWH as the standard of care. ASCO recommendations propose unfractiona ted heparin, fondaparinux or LMWH as a firstline trea tment, unless contraindicated due to high bleeding risk or active bleeding. Prophylactic dosages at levels of 30005000 antiFxa units per day have proven more effective than and as safe as lower doses. Treatment should begin 1224 h pre or 624 h postoperatively and last 710 d. The combination of pharmacologic and mechanical prophylaxis, such as compression stockings and intermittent pneumatic compression devices, may be more efficient, especially in the highrisk group of patients. Extended thromboprophylaxis up to 28 d shou ld be taken into serious consideration only in highrisk patients who fulfill the following criteria, including cancer related stage Ⅲ/Ⅳ, upper GI cancer, histological fea tures of adenocarcinoma, thrombocytosis, leucocytosis, elevated Ddimer and CRP. Patientrelated factors refer Perfusion Scanning may be used when CTPA or Pul monary Angiography are contraindicated [25] . Finally, PE demonstrates increased signal intensity within the pul monary artery during magnetic resonance angiography with intravenous administration of gadolinium. Sensitivity and specificity are high for central, lobar, and segmental emboli, while subsegmental emboli render magnetic resonance angiography inadequate [26] (Table 2) .
THERAPEUTIC APPROACH
VTE remains the second most common cause of death in cancer patients and constitutes an independent pro gnostic factor for mortality [27] . Moreover, recurrent VTE and major bleeding complications are higher in cancer patients, even if they receive anticoagulation therapy. Patients with upper GI malignancies, such as hepatobili ary and gastroesophageal cancer, are in great danger of VTE, with pancreatic cancer presenting the highest VTE prevalence. In advanced pancreatic cancer patients, relevant risk is as high as 25%, and asymptomatic VTE incidence is up to 60%. GI cancers are frequently treated with antiangiogenic or chemotherapeutic agents, such as cisplatin and irinotecan, which are associated with increased risk for VTE as well as combined neoad juvant chemoradiotherapy [28] . It is estimated that ch emotherapy provokes an inflammatory response due to endothelial disruption. In particular, IL1 and TNFa, among other cytokines, diminish the concentration of anticoagulant proteins, such as antithrombin Ⅲ and pro tein C. The procoagulant reaction is reinforced by incre ased TF expression, and is maintained for up to 6 mo after induction of chemoradiation, thus implying an in WJGO|www.wjgnet.com As far as longterm prevention of VTE is concerned, ASCO guidelines suggest the use of LMWH as the stan dard of care. If this is unavailable, vitamin K antagonists (VKA) are used. Novel Oral Anticoagulants (NOACs) are currently not suggested for patients with GI cancer and VTE due to the limited data available in patients with malignancy. Treatment should last for 6 mo. ESCO and American Society of Haematology guidelines recommend the use of LMWH for 6 mo. ESCO specifically proposes an initial dose of LMWH 100% for 1 mo and 75%80% of the initial dose for 5 mo thereafter. Additionally, the Mayo Clinic suggests that anticoagulants should be con tinued until there is no evidence of active malignancy, either as evidence of imaging or cancerrelated treat ment, while German guidelines propose LMWH for 36 mo and highlight that prophylaxis could last for a lifetime in persistent cancers [32] . NonvitaminK NOACs have been introduced in the treatment of VTE associated with GI cancer. As the aforementioned guidelines state, the use of NOACs are currently not recommended due to limited data in cancer patients. On the other hand, available anticoagulants exhibit certain disadvantages. Unfractionated heparin requires platelet monitoring and daily injections, which are highly inconvenient. Also, it is associated with hepa rininduced thrombocytopenia, types Ⅰ and Ⅱ, bleeding and osteoporosis. LMWH is contraindicated in renal impa irment, adding to its drawbacks. VKA, such as warfarin, require INR monitoring and have multiple drug and food interactions. A narrow therapeutic window, delayed onset of action and bleeding risk render VKA inadequate and inferior to LMWH [28] . The family of NOACs includes dabigatran etexilate, rivaroxaban, apixaban and edoxaban, each one with their own special pharmacokinetics and pharmacodyna mics [33] . Dabigatran etexilate is a direct thrombin (fac tor Ila) inhibitor. It is administered orally and presents a halflife of 1214 h and a rapid onset of action. Its bioavailability does not exceed 10% (37%), and its ab sorption is facilitated by acids. Its excretion is primarily in urine (80%), so caution is required for patients with renal impairment, as its halflife can be increased up to 34 h. More specifically, it is contraindicated when creatinine clearance (CrCl) is under 30 mL/min. Its cle arance is also dependent on the Pglycoprotein transport pathway. In addition, routine monitoring is not required because of predictable pharmacokinetics. In the RE COVER, RESONATE and REMEDY phase Ⅲ clinical tri als, dabigatran showed noninferiority to warfarin and superiority to placebo. It is FDA approved for VTE proph ylaxis after hip and knee arthroplasty, stroke prevention in patients with nonvalvular atrial fibrillation, and VTE treatment. As for adverse effects, dyspepsia is the only one that occurs more frequently with dabigatran than with warfarin [28, 33] . Rivaroxaban is a direct inhibitor of factor Xa. It is orally administered and has a halflife of 711 h, with a rapid onset of action as well [34] . Its bioavailability is excellent (80%100%). Significant food interactions have not been reported. It is a substrate of the cytochrome P450 system, especially CYP3A4 and Pglycoprotein, and is excreted by both the renal and hepatic systems, demanding extreme caution in patients with renal or hepatic insufficiency [33] . More specifically, it is contra indicated when CrCl is under 30 mL/min in haemodia lysis and in patients with ChildPugh B or C cirrhosis. Ad ditionally, monitoring is not required. In the EINSTEIN DVT and EINSTEINExtension phase Ⅲ clinical trials, rivaroxaban presented noninferiority to VKA/LMWH WJGO|www.wjgnet.com and superiority to placebo, respectively. It is also FDA ap proved with the same indications as dabigatran [28] . Apixaban appears to have the same mode of action and route of administration as rivaroxaban. It has a halflife of 12 h, and a bioavailability of about 50%. It is metabolized by Pglycoprotein, the cytochrome 450 system, and the CYP3A4 pathway. Its excretion is in urine (25%), and the drug is contraindicated when CrCl is under 15 mL/min. Edoxaban inhibits factor Xa and is orally administered. It has a halflife of 810 h and good bioavailability (62%). It is excreted primarily by the hepatobiliary route and secondarily in the urine. Also, it is metabolized by both Pglycoprotein and the CYP3A4 pathway. As mentioned for the other NOACs, monitoring is not required. Both apixaban and edoxab an are FDA approved for nonvalvular atrial fibrillation, VTE treatment and prevention after major orthopaedic surgery [28, 33] . As far as dosing frequency is concerned, dabigatran and apixaban require 110150 mg and 2.55 mg twice a day, respectively, while rivaroxaban and edoxaban necessitate 1030 mg and 1530 mg once daily, respe ctively [33] . Apixaban remains the safest of the NOACs, showing reduced risk of major or clinicallyrelevant mi nor bleeding at a statistically significant level, with da bigatran taking the second place. Additionally, apixaban and rivaroxaban pose a significantly lower risk for major bleeding compared with LMWH or VKA, a fact which may be of particular clinical importance [35] . In conclusion, differences between doses of dabigatran and apixab an, as well as the correlations between the safety and timing differences between dabigatran or apixaban and rivaroxaban or edoxaban, are summarized in Table 3 .
CONCLUSION
VTE refers to both DVT and PE and is highly associated with malignancy, with HPB and gastric cancer ranking first [36] . CTPA is the initial diagnostic modality, while ul trasonography is preferred for DVT [37] . LMWH is used pre or 624 h postoperatively and should continue for 710 d. Extension up to 28 d is highly recommended for major abdominal or pelvic surgical procedures [3842] . NOACs are promised to revolutionize current treatment and bring together efficacy and many benefits for pa tients. However, the use of NOACs for VTE prophylaxis is certainly debatable. Potential drug interactions with chemotherapeutic components, GI abnormalities, and hepatic and renal insufficiency remain significant de terminants of NOAC administration [4345] . Therefore, bio availability may not reach desirable levels [46] . The lack of rapid reversal agents also prevents the use of these agents for invasive procedures and thrombocytopenia. Furthermore, cancer patients are at a greater risk of bleeding than noncancer patients due to chemotherapy induced thrombocytopenia and antiangiogenic therapy. Moreover, a reduction in circulating proteins and album ins could influence the binding levels of NOACs. Thus, a comparative study of NOACs with the current curative approach, LMWH, may clarify this dispute.
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